 Rhabdomyosarcoma
"Rhabdomyosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
| Descriptor ID |
D012208
|
| MeSH Number(s) |
C04.557.450.590.550.660 C04.557.450.795.550.660
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rhabdomyosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Rhabdomyosarcoma".
This graph shows the total number of publications written about "Rhabdomyosarcoma" by people in this website by year, and whether "Rhabdomyosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2013 | 3 | 0 | 3 | | 2014 | 1 | 1 | 2 | | 2015 | 0 | 1 | 1 | | 2017 | 3 | 2 | 5 | | 2018 | 2 | 0 | 2 | | 2019 | 1 | 1 | 2 | | 2020 | 3 | 2 | 5 | | 2021 | 4 | 0 | 4 | | 2022 | 5 | 0 | 5 | | 2023 | 4 | 0 | 4 | | 2024 | 7 | 0 | 7 | | 2025 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Rhabdomyosarcoma" by people in Profiles.
-
Onwuka EA, Magyar CL, Martin-Giacalone BA, Scheurer ME, Marquez-Do DA, Zobeck M, Atkinson EG, Rudzinski ER, Arnold MA, Barkauskas DA, Hall D, Khan J, Shern JF, Scheet P, Crompton B, Linardic CM, Hawkins DS, Venkatramani R, Mirabello L, Huff CD, Richard MA, Lupo PJ. The impact of genetic ancestry on survival outcomes in pediatric rhabdomyosarcoma: A report from the Children's Oncology Group. HGG Adv. 2025 Jul 10; 6(3):100466.
-
Dela Cruz FS, Fox E, DuBois SG, Friedman GK, Croop JM, Kim A, Morgenstern DA, Balis FM, Macy ME, Pressey JG, Watt T, Krystal JI, Vo KT, Mody R, Laetsch TW, Weigel BJ, O'Hara K, He CS, Aluri J, Okpara CE, Glade Bender JL. A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors. Pediatr Blood Cancer. 2025 Jul; 72(7):e31692.
-
Aye JM, Xue W, Gao Z, Ladra M, Indelicato DJ, Sheyn A, Dasgupta R, Arnold MA, Shenoy A, Linardic CM, Venkatramani R. Nonorbital, Nonparameningeal Head and Neck Rhabdomyosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2025 Jun; 72(6):e31673.
-
Hsieh J, Danis EP, Owens CR, Parrish JK, Nowling NL, Wolin AR, Purdy SC, Rosenbaum SR, Ivancevic AM, Chuong EB, Ford HL, Jedlicka P. Dependence of PAX3-FOXO1 chromatin occupancy on ETS1 at important disease-promoting genes exposes new targetable vulnerability in Fusion-Positive Rhabdomyosarcoma. Oncogene. 2025 01; 44(1):19-29.
-
Casey DL, Murphy ES, Shen CJ, Milgrom SA, Larrier NA, Bradley JA, Ladra MM, Indelicato DJ, Hill-Kayser CE, Borinstein SC, Luo LY. Metastatic-Site Radiation Therapy for Ewing Sarcoma and Rhabdomyosarcoma: Consensus Guidelines From the National Pediatric Cancer Foundation. Pract Radiat Oncol. 2025 Mar-Apr; 15(2):180-186.
-
Ou JY, Kaddas HK, Alonzo TA, Spector LG, Fallahazad N, Owens E, Collin LJ, Green AL, Kirchhoff AC. Sociodemographic and Socioeconomic Factors Correlate with Late-Stage Pediatric Hodgkin Lymphoma and Rhabdomyosarcoma: A Report from the Children's Oncology Group Registries. Cancer Epidemiol Biomarkers Prev. 2024 Oct 02; 33(10):1327-1338.
-
Schloemer NJ, Xue W, Qumseya A, Luo LY, Hiniker SM, Lautz TB, Rhee DS, Arnold MA, Venkatramani R. Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies. Pediatr Blood Cancer. 2024 Oct; 71(10):e31200.
-
Gupta AA, Xue W, Harrison DJ, Hawkins DS, Dasgupta R, Wolden S, Shulkin B, Qumseya A, Routh JC, MacDonald T, Feinberg S, Crompton B, Rudzinski ER, Arnold M, Venkatramani R. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Lancet Oncol. 2024 Jul; 25(7):912-921.
-
Metts JL, Aye JM, Crane JN, Oberoi S, Balis FM, Bhatia S, Bona K, Carleton B, Dasgupta R, Dela Cruz FS, Greenzang KA, Kaufman JL, Linardic CM, Parsons SK, Robertson-Tessi M, Rudzinski ER, Soragni A, Stewart E, Weigel BJ, Wolden SL, Weiss AR, Venkatramani R, Heske CM. Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials. Cancer. 2024 Nov 15; 130(22):3785-3796.
-
Harrison DJ, Qumseya A, Xue W, Arnold M, Lautz TB, Hiniker SM, Thomas SM, Venkatramani R, Weiss AR, Mascarenhas L. Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer. 2024 Apr; 71(4):e30847.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|